| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Operating revenues: | ||||||||
License revenues | ||||||||
- | - | - | - | - | - | 0 | - | - |
Operating expenses: | ||||||||
Research and development | ||||||||
6,674 | 7,900 | 7,549 | 7,142 | 6,338 | 4,522 | 0 | 0 | 0 |
General and administrative | ||||||||
3,902 | 3,693 | 3,392 | 3,125 | 3,038 | 2,739 | 0 | 0 | 0 |
Total operating expenses | ||||||||
- | - | - | - | - | - | - | - | 0 |
Operating loss | ||||||||
-10,576 | -11,593 | -10,941 | -9,767 | -8,876 | -6,761 | 0 | 0 | 0 |
Other (income) expense: | ||||||||
Governmental assistance - research incentives | ||||||||
797 | 856 | 832 | 765 | 657 | 1,214 | 0 | 0 | 0 |
Other (income) expense, net | ||||||||
-12 | 119 | 13 | 12 | -29 | -68 | 0 | 0 | 0 |
Change in fair value of warrant liability | ||||||||
- | - | - | - | - | 39 | 0 | 0 | 0 |
Total other (income) expense | ||||||||
1,165 | 975 | 489 | 421 | 272 | 1,107 | 0 | 0 | 0 |
Loss before income tax expense | ||||||||
-9,791 | -10,618 | -10,096 | -8,990 | -8,248 | -5,654 | 0 | 0 | 0 |
Income tax expense | ||||||||
31 | 31 | 35 | 80 | 88 | 80 | 0 | 0 | 0 |
Net loss | ||||||||
-9,822 | -10,649 | -10,131 | -9,070 | -8,336 | -5,734 | 0 | 0 | 0 |
Other comprehensive income | ||||||||
Unrealized gain on marketable securities | ||||||||
39 | 2 | 0 | 0 | 0 | - | - | - | - |
Net loss and comprehensive loss | ||||||||
-9,783 | -10,647 | -10,125 | -9,059 | -8,333 | -5,734 | 0 | 0 | 0 |
Basic and diluted net loss per share (in dollars per share) | ||||||||
-0.19 | -0.21 | -0.20 | -0.21 | -0.27 | -0.24 | -0.18 | -0.22 | -0.10 |
Weighted average shares outstanding – basic and diluted (in shares) | ||||||||
13,107 | 12,007 | 12,006 | 11,979 | 11,956 | 8,769 | 7,836 | 7,821 | 6,546 |